ANYO Labs is an early drug discovery company with a novel patent pending artificial intelligence scoring method unlike any other on the market. With the help of molecular biology scientists and professor, this unique method allows for extreme data and energy efficient ways of finding drug compounds for further testing in the lab and clinical trials. The market potential is very large and is targeted towards chemisty research facilities as well as small and big pharmaceutical institutions. Modern drug discovery suffers from major bottlenecks in speed, accuracy, and in finding new and unique drugs. To solve this, the research team at GU has for 2 years developed i-TripleD: a novel machine learning method that goes beyond state-of-the-art, using a totally unique approach to molecular screening. Our scoring function (iScore) is trained against the largest datasets available that were manually curated. The ML-method is based on new levels of sophistication, leading to unprecedented accuracy in scoring power, ranking power and screening power. With our novel Ultra-Fast Screening approach, we can furthermore screen compounds several orders of magnitude faster than any current software. The most similar and fastest screening methods nowadays require around 112 times more computing time, thereby also 112 times more energy expenditure as a byproduct. To add to this, the classic and most used conformational sampling tools require over 1600 times more time but perform with over 3 times lower accuracy. All molecules are filtered against a state-of-the-art ML-based ADMET and Synthetic feasibility module, containing 41 different assessments/assays. At the moment, we also are working with integrating our protein-protein interaction models to be integrated with our screening capabilities.